Anabolic steroids in myelodysplastic syndromes: A systematic review. (July 2020)

• Record Type: Journal Article
• Authors: Garcia-Horton, Alejandro; Valliere, Yashoda; Lazo-Langner, Alejandro
• Is Part Of: Leukemia research. Volume 94(2020)
• Publication Date: 2020-07
• Subjects: Myelodysplastic syndrome -- Danazol -- Anabolic steroid; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2020.106370
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: Anabolic steroids such as danazol are widely used in the treatment of MDS. We conducted a systematic review to assess the evidence for their use. Study design was variable and the results indicated mixed outcomes. Risk-of-bias and study quality tools demonstrated that most studies were flawed. Danazol remains acceptable in low-risk MDS, but randomized trials are needed.